Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Do Hedge Funds Think of Exelixis, Inc. (EXEL)?

Page 1 of 2

Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients’ money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth depends on it. Regardless of the various methods used by elite investors like David Tepper and Dan Loeb, the resources they expend are second-to-none. This is especially valuable when it comes to small-cap stocks, which is where they generate their strongest outperformance, as their resources give them a huge edge when it comes to studying these stocks compared to the average investor, which is why we intently follow their activity in the small-cap space.

Is Exelixis, Inc. (NASDAQ:EXEL) a buy right now? Hedge funds are becoming hopeful. The number of long hedge fund positions improved by 2 in recent months. EXEL was in 12 hedge funds’ portfolios at the end of the third quarter of 2015. There were 10 hedge funds in our database with EXEL holdings at the end of the previous quarter. At the end of this article we will also compare EXEL to other stocks including Archrock Inc. (NYSE:AROC), KB Home (NYSE:KBH), and Vonage Holdings Corp. (NYSE:VG) to get a better sense of its popularity.

Follow Exelixis Inc. (NASDAQ:EXEL)
Trade (NASDAQ:EXEL) Now!

With all of this in mind, let’s check out the recent action surrounding Exelixis, Inc. (NASDAQ:EXEL).

Hedge fund activity in Exelixis, Inc. (NASDAQ:EXEL)

At Q3’s end, a total of 12 of the hedge funds tracked by Insider Monkey were long this stock, a change of 20% from one quarter earlier. With hedgies’ positions undergoing their usual ebb and flow, there exists a few noteworthy hedge fund managers who were boosting their stakes substantially (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Kenneth Tropin’s Graham Capital Management has the most valuable position in Exelixis, Inc. (NASDAQ:EXEL), worth close to $15.9 million, corresponding to 1.9% of its total 13F portfolio. The second most bullish fund manager is Great Point Partners, managed by Jeffrey Jay and David Kroin, which holds a $8.9 million position; the fund has 3.5% of its 13F portfolio invested in the stock. Remaining hedge funds and institutional investors that hold long positions include Mark Kingdon’s Kingdon Capital, Richard Driehaus’s Driehaus Capital and Peter Muller’s PDT Partners.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!